bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.09.08.750172

Causal variant underestimation is a major overlooked driver of sequence-to-function model underperformance

Abstract

Deep learning sequence-to-function (S2F) models represent tremendous promise for functionally fine-mapping causal variants associated with traits and disease. Yet it remains unclear precisely how effective they are at this task. Generally, S2F models perform well at classifying putatively causal expression quantitative trait loci (eQTL) SNVs, yet dramatically underperform linear baselines at ranking different individuals' gene expression values from their whole genome sequence, which directly calls into question their ability to fine-map a locus by properly weighting the effects of variants onto gene expression. Here, using the state-of-the-art S2F model AlphaGenome, we systematically compared predicted effect sizes for fine-mapped eQTLs to nearby putatively non-causal SNVs, finding that AlphaGenome pervasively underestimates the effects of most causal variants and fails to successfully fine-map eQTLs in most loci for this reason. We show that misdirected variant effect predictions and negative cross-individual correlations, widely cited as major challenges facing S2F expression modeling, are not egregious errors but a chance consequence of weak, noisy attributions when causal variants are underestimated. Our results suggest that a failure to detect local variant effects onto enhancer activity is a cause of underestimation. Additionally, we find that underestimated variants are enriched far from their target gene, suggesting inadequate enhancer-gene linking causes underestimation even when local effects are well-detected. Finally, our results clarify when S2F models are reliable for fine-mapping objectives: while they pervasively underestimate most causal variants, demonstrating limited fine-mapping utility for most loci, the top 0.1 most prominent variant effect predictions are strongly enriched for causal variants with directionally correct predictions that are consistent across model replicates, suggesting extremely strong predictions are broadly trustworthy. Our results demonstrate that causal variant underestimation is a core issue facing S2F expression predictors, with future improvements dependent on better local activity detection and enhancer-gene linking.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Drusinsky, S., Pollard, K. S.. 2026-09-11. Causal variant underestimation is a major overlooked driver of sequence-to-function model underperformance. https://doi.org/10.64898/2026.09.08.750172

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗